🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

EUS Guided HVA and PVA for Circulating Tumor DNA in Patients

RecruitingNAAges any - anyAllChinese University of Hong Kong
NCT04782557 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of technologies for ctDNA analysis have presented an attractive opportunity for minimally invasive "liquid biopsy" genomic diagnostics. The investigators plan to perform EUS-guided portal vein and hepatic vein aspiration in GI cancers patients. The aim of the current study is thus to examine the concentration of ctDNA in portal vein (EUS-guided PVA), hepatic vein (EUS-guided HVA) and peripheral blood to understand the first pass effect of the liver with gastrointestinal (GI) cancers, and the possibility of using ctDNA as a marker for preoperative staging, restaging after neoadjuvant chemotherapy, and monitoring for recurrence.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria: 1. Age \>= 18 years old 2. Newly diagnosed stage II-IV distal gastric cancer, pancreatic cancer or colorectal cancer 3. Undergoing treatment with either: 1. Surgery 2. Neoadjuvant chemotherapy 3. Neoadjuvant chemoirradiation 4. Palliative chemotherapy/ immunotherapy Exclusion criteria: <!-- --> 1. Synchronous cancer of other sites 2. Cardia, high lesser curve tumors, oesophagogastric junction tumors 3. Presence of bulky lymph nodes at lesser curve/ coeliac region precluding a clear EUS puncture site to portal vein and hepatic vein 4. Patients with coagulopathy (international normalized ratio \>1.3, partial thromboplastin time greater than twice that of control), platelet count \<50,000x103/uL 5. Patients unwilling to undergo follow-up assessments 6. Patients with liver cirrhosis, portal hypertension and/ or gastric varices 7. Patient refusal to participate \-
💊

What it tests

  • EUS-guided portal vein and hepatic vein aspiration
📍

Where

1 site
The Chinese University of Hong Kong
Hong Kong, Hong Kong
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy